Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels

Exclusion Criteria

• •perianal CD exclusively
• •disease limited to the rectum in patients with UC (i.e., disease must extend ≥ 15 cm from the anal verge)
• •patients with known antibodies to IFX (ADAs) at baseline
• •a contraindication to infliximab therapy
• •a contraindication to endoscopy
• •an ostomy
• •planned surgery
• •evidence of severe or unstable hepatic, gastrointestinal, cardiovascular, respiratory, neurological, psychiatric, hematological or renal disease at the discretion of the investigator,
• •Pregnancy or breastfeeding,
• •treatment with any investigational drug in the past 30 days, or 5 half lives (whichever is longer).